Association of serum NRF2 levels with in-hospital MACE in STEMI patients undergoing emergency PCI: an observational cohort study

To investigate the association between pre-PCI serum NRF2 levels and in-hospital MACE among STEMI patients undergoing emergency PCI, and to evaluate its discriminatory performance alone and in combination with conventional cardiac biomarkers. This prospective observational cohort study consecutively enrolled 341 STEMI patients undergoing emergency PCI from January 2023 to September 2025. Serum NRF2, NOX2, MPO, IL-6, and IL-1β were quantified using ELISA after admission and before PCI. In-hospital MACE was adjudicated from admission to discharge. Group comparisons, Spearman correlation, ROC analysis, a discharge-competing-risk analysis, and multivariable binary logistic regression were conducted. During hospitalization, 57 patients (16.7%) experienced in-hospital MACE. Patients who experienced in-hospital MACE had significantly lower serum NRF2 levels than those without events. Serum NRF2 showed significant negative correlations with cTnI, CK-MB, MPO, and IL-6. In ROC analysis, NRF2 alone demonstrated good discrimination for in-hospital MACE with an AUC of 0.760 (95% CI 0.701–0.819); the optimal cutoff was 8.8 ng/mL, yielding 80.7% sensitivity and 62.7% specificity. A combined model including NRF2, cTnI, and NT-proBNP showed a higher apparent AUC, reaching an AUC of 0.823 (95% CI 0.761–0.885), with sensitivity of 61.4% and specificity of 89.8%. Competing-risk cumulative incidence curves showed more frequent in-hospital MACE in the lower NRF2 group. In multivariable logistic regression, NRF2 remained associated with lower adjusted odds of in-hospital MACE (OR 0.556, 95% CI 0.387–0.799, p = 0.002). Lower serum NRF2 levels corresponded to higher in-hospital MACE risk among STEMI patients undergoing emergency PCI. NRF2 showed good discriminatory ability, and its combination with cTnI and NT-proBNP showed a higher apparent AUC, warranting external validation before clinical risk-stratification use.

Authors

Institutions

Publication Details

Journal
BMC Cardiovascular Disorders
Published
2026-11-18
DOI
https://doi.org/10.1186/s12872-026-06987-z
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of serum NRF2 levels with in-hospital MACE in STEMI patients undergoing emergency PCI: an observational cohort study

Baoping Jia, Yuehui Sun, Xiaobin Zheng, Rui Yan et al.
3 links
BMC Cardiovascular Disorders
Acute Myocardial Infarction Research
article

Association of serum NRF2 levels with in-hospital MACE in STEMI patients undergoing emergency PCI: an observational cohort study

Baoping Jia, Yuehui Sun, Xiaobin Zheng, Rui Yan, Jin Tian, Na Li, Xiaojuan Zhang
article en

Abstract

To investigate the association between pre-PCI serum NRF2 levels and in-hospital MACE among STEMI patients undergoing emergency PCI, and to evaluate its discriminatory performance alone and in combination with conventional cardiac biomarkers. This prospective observational cohort study consecutively enrolled 341 STEMI patients undergoing emergency PCI from January 2023 to September 2025. Serum NRF2, NOX2, MPO, IL-6, and IL-1β were quantified using ELISA after admission and before PCI. In-hospital MACE was adjudicated from admission to discharge. Group comparisons, Spearman correlation, ROC analysis, a discharge-competing-risk analysis, and multivariable binary logistic regression were conducted. During hospitalization, 57 patients (16.7%) experienced in-hospital MACE. Patients who experienced in-hospital MACE had significantly lower serum NRF2 levels than those without events. Serum NRF2 showed significant negative correlations with cTnI, CK-MB, MPO, and IL-6. In ROC analysis, NRF2 alone demonstrated good discrimination for in-hospital MACE with an AUC of 0.760 (95% CI 0.701–0.819); the optimal cutoff was 8.8 ng/mL, yielding 80.7% sensitivity and 62.7% specificity. A combined model including NRF2, cTnI, and NT-proBNP showed a higher apparent AUC, reaching an AUC of 0.823 (95% CI 0.761–0.885), with sensitivity of 61.4% and specificity of 89.8%. Competing-risk cumulative incidence curves showed more frequent in-hospital MACE in the lower NRF2 group. In multivariable logistic regression, NRF2 remained associated with lower adjusted odds of in-hospital MACE (OR 0.556, 95% CI 0.387–0.799, p = 0.002). Lower serum NRF2 levels corresponded to higher in-hospital MACE risk among STEMI patients undergoing emergency PCI. NRF2 showed good discriminatory ability, and its combination with cTnI and NT-proBNP showed a higher apparent AUC, warranting external validation before clinical risk-stratification use.

BMC Cardiovascular Disorders
Shanxi Cardiovascular Hospital (CN)
Good health and well-being
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon